Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Authors
Posts by lungcanc
lungcanc
526 POSTS
0 COMMENTS
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small...
lungcanc
Breaking News Briefs
lungcanc
Frances A. Shepherd, OC, OOnt, MD, FRCPC
lungcanc
Raymond Osarogiagbon, MBBS, FACP
lungcanc
ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell...
lungcanc
IASLC 18th World Conference on Lung Cancer
lungcanc
IASLC Leader Elected President of ESMO for 2020–2021: Solange Peters, MD,...
lungcanc
PJ Souquet, MD
lungcanc
Ellen V. Sigal, PhD: Leading the Cancer Research Advocacy Community
lungcanc
Breaking News Briefs
lungcanc
1
...
33
34
35
...
53
Page 34 of 53
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
